IL28B polymorphism and virological responseduring 12 weeks of pegylated interferon and ribavirin treatment in Polish chronic hepatitis C patients

摘要

Background: Identification of molecular markers playing role in predicting anti-HCV treatment outcome would facilitate therapy optimizing. GWAS has demonstrated that genetic polymorphism at rs12979860 (C/T) near IL28B gene is a strong predictor of Sustained Virological Response (SVR) in chronic hepatitis C (CHC) patients treated with pegylated interferon α and ribavirin (pegIFN-α + RBV). Moreover, monitoring viral kinetics can help identify patients with high chances of treatment success. The aim of this study was to examine predictive value of IL28B SNP rs12979860 (C/T) for on-treatment virological response in Polish CHC patients treated with pegIFN-α and RBV.